Next |
home / stock / cvac / cvac message board
Subject | By | Source | When |
---|---|---|---|
$CVAC CureVac NV | mick | investorshub | 04/30/2023 10:27:40 PM |
$CVAC CureVac NV | mick | investorshub | 04/15/2023 7:10:09 PM |
$CVAC CureVac NV | mick | investorshub | 04/15/2023 2:57:33 PM |
$CVAC CureVac NV | mick | investorshub | 04/15/2023 2:57:32 PM |
$CVAC CureVac NV | mick | investorshub | 02/26/2023 11:52:14 PM |
$CVAC CureVac NV | mick | investorshub | 02/05/2023 11:46:59 PM |
znewcar1: $CVAC 20% v5,6M c12.49 f190,283M H12.60 ML5.63 YL9.83 | znewcar1 | investorshangout | 01/10/2023 10:35:11 PM |
znewcar1: $CVAC 25% v6,7M c10.36 f190,283M H11.14 gapGoFade S10? | znewcar1 | investorshangout | 01/09/2023 11:10:36 PM |
znewcar1: $CVAC 29% v2,7M C8.26 f190,283M H8.30 ml5.63 | znewcar1 | investorshangout | 01/06/2023 10:04:06 PM |
it is relative CureVac ($CVAC) Receives a Buy | mick | investorshub | 12/20/2022 12:30:23 AM |
$CVAC CureVac NV | mick | investorshub | 12/20/2022 12:28:58 AM |
i think $CVAC is ah buyout candidate /\ | mick | investorshub | 12/20/2022 12:28:58 AM |
$CVAC CureVac NV | mick | investorshub | 12/18/2022 10:35:11 PM |
$CVAC CureVac NV | mick | investorshub | 10/23/2022 5:49:02 PM |
$CVAC CureVac N.V. | mick | investorshub | 08/31/2022 10:29:19 PM |
we don't show quote ????? | mick | investorshub | 08/31/2022 10:28:07 PM |
we don't show quote ????? | mick | investorshub | 08/31/2022 10:28:06 PM |
CureVac ($CVAC) Receives a Buy from Berenberg Bank | mick | investorshub | 08/31/2022 10:26:54 PM |
$CVAC CureVac NV | mick | investorshub | 07/18/2022 12:08:11 AM |
Interesting new Beneficial Owners recently. Taken an | sdy | investorshub | 07/01/2022 7:06:38 PM |
News, Short Squeeze, Breakout and More Instantly...
CureVac N.V. Company Name:
CVAC Stock Symbol:
NASDAQ Market:
Canadian Biotech company Acuitas Therapeutics and Germany-based CureVac NV (NASDAQ:CVAC) have settled Acuitas’ lawsuit ov...
Phase 1 part of combined Phase 1/2 study initiated as part of pandemic preparedness against highly pathogenic avian influenza (H5N1) virus, considered to be potential future pandemic threat Study will assess monovalent vaccine candidate, encoding an influenza A H5-antigen using proprietary s...
Mr. Ramanayake brings more than fifteen years of experience in biopharma company development and deal-making Strong track record of successful clinical collaborations, M&A, asset in-licensing and strategic financing initiatives across multiple therapeutic areas TÜBINGEN, GERMA...